Ethamsylate is believed to correct abnormal platelet adhesion, so reducing capillary bleeding.
It is licensed in short courses for reducing menorrhagia and also for the prophylaxis and treatment of periventricular haemorrhage in low birth weight infants.
It is contra-indicated in porphyria and may cause nausea, headaches and rashes.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.